Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: Comparison with enalapril

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 8, 2005, Pages 964-971

  Kasama, Shu ^a   Toyama, Takuji ^a   Kumakura, Hisao ^b   Takayama, Yoshiaki ^b   Ichikawa, Shuichi ^b   Suzuki, Tadashi ^a   Kurabayashi, Masahiko ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Cardiovasc Hosp of Central Japan   (Japan)

Author keywords

123I MIBG; Angiotensin converting enzyme inhibitor; Heart failure

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; NITRATE; PERINDOPRIL; SPIRONOLACTONE;

ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART NERVE; HEART PROTECTION; HEART RATE; HEART VOLUME; HUMAN; IMAGING; MALE; NERVE CONDUCTION; PLASMA; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPATHETIC NERVE; SYSTOLE; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ENALAPRIL; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MALE; PERINDOPRIL; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 23944473695     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1786-z     Document Type: Article

References (37)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Co-operative North Scandinavian Enalapril Survival Study (CON SENSUS). N Engl J Med 1987;316:1429-35.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
3. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
4. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, at al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-77.
5. Masuell M, Brusca G, Pardo A, Pineiro D, Checkerdhemian S, Forcada P. ACE inhibitors in heart failure switching from enalapril to perindopril. Curr Med Res Opin 2002;18: 296-302.
6. Watanabe K, Saito Y, Ma M, Wahed M, Abe Y, Hirabayashi K, et al. Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J Cardiovasc Pharmacol 2003; 42: S105-9.
7. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78:1192-9.
8. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
9. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471-7.
10. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathyClinical meaning of iodine 123-metoiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001;141:645-52.
11. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-9.
12. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40:217-23.
13. Toyama T, Hoshizaki H, Seki R, Isobe N, Adachi H, Naito S, et al. Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. J Nucl Med 2003;44:1604-11.
14. Kasama S, Toyama T, Hoshizaki H, Oshima S, Taniguchi K, Suzuki T, et al. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 2002;122:542-8.
15. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279-85.
16. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:574-81.
17. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44:884-90.
18. Kasama S, Toyama T, Kumakura H, Takayama Y, Ishikawa T, Ichikawa S, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med 2004; 45:1108-13.
19. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction. Eur J Nucl Med Mol Imaging 2005;32:322-8.
20. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-7.
21. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
22. 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy. J Nucl Med 2004;45:1878-84.
23. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.
24. Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y, et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87:3936-40.
25. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.
26. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69: 475-82.
27. Hokimoto S, Yasue H, Fujimoto K, Yamamoto H, Nakao K, Kaikita K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996;94:1513-8.
28. Mizuno Y, Yasue H, Yoshimura M, Fujii H, Yamamoto N, Nakayama M, et al. Effects of perindopril on aldosterone production in the failing human heart. Am J Cardiol 2002;89:1197-200.
29. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-82.
30. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996;93:1148-54.
31. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
32. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
33. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
34. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
35. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
36. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
37. Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto H, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004;6:295-300.